AWM
CPRX

AE Wealth Management’s Catalyst Pharmaceutical CPRX Stock Holding History

AE Wealth Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-11,696
Closed -$218K – 1895
2022
Q4 		$218K Buy
+11,696
New +$180K ﹤0.01% 1634

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $18.8B AUM 29.2% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

AE Wealth Management's CPRX Position: Q1 2023 in Review

AE Wealth Management sold out of Catalyst Pharmaceutical (CPRX) in Q1 2023, closing a stake of 11,696 shares — an estimated $218K sold.

AE Wealth Management first reported a position in CPRX in Q4 2022 and held it in 1 quarter. The position peaked at $218K in Q4 2022. 259 funds tracked by Wall St. Rank hold CPRX as of Q1 2023.

  • AE Wealth Management reported no remaining Catalyst Pharmaceutical position as of Q1 2023 after selling out during the quarter.
  • AE Wealth Management sold 11,696 Catalyst Pharmaceutical shares in Q1 2023, an estimated $218K.
  • AE Wealth Management first reported a position in Catalyst Pharmaceutical in Q4 2022 and held it in 1 quarter.
  • AE Wealth Management's Catalyst Pharmaceutical position peaked at $218K in Q4 2022.
  • 259 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2023.

Based on AE Wealth Management's 13F filing for Q1 2023, filed 14 Apr 2023.